AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02772757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coupler-based fitting
Description: coupler-based fitting using measured RECDs
Study NCT03598907 — intervention group
Intervention type: OTHER
Intervention: Fresh frozen plasma
Description: Fresh frozen plasma will be used according to anaesthetist ,,blind,, decision
Study NCT00400803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Carboplatin, Bevacizumab
Description: Patients will be treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
Study NCT03946722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH analogue downregulation
Description: Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Participants will be exposed to one week of downregulation using a GnRH analogue in the standard downregulation arm and 6 weeks of downregulation using a GnRH analogue in the modified downregulation arm.
Study NCT03946722 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GnRH analogue downregulation
Description: Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Participants will be exposed to one week of downregulation using a GnRH analogue in the standard downregulation arm and 6 weeks of downregulation using a GnRH analogue in the modified downregulation arm.
Study NCT03946722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant questionnaire
Description: Participant will be offered the opportunity to complete an adenomyosis symptom assessment questionnaire at the start of their treatment, and again two months after completion of treatment.
Study NCT03946722 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Participant questionnaire
Description: Participant will be offered the opportunity to complete an adenomyosis symptom assessment questionnaire at the start of their treatment, and again two months after completion of treatment.
Study NCT01296048 — intervention group
Intervention type: DEVICE
Intervention: Comparison test
Description: Scaleman Body Fat Scales, FS-148BW1, accuracy: ±0.1kg and range: 0-180kg.
Study NCT04108117 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic nipple sparing mastectomy
Description: Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.
Study NCT01135563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine and Sirolimus
Description: Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.~Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough
Study NCT04541277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab combined with DNA demethylation agent +/- CAG regimen
Study NCT00705744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic acid (Dermacyd Femina)
Study NCT01375855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal Coronary Angioplasty
Description: Coronary artery stent implantation
Study NCT03618589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
Study NCT03618589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opioid
Description: Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
Study NCT03618589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid
Description: Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
Study NCT05288907 — intervention group
Intervention type: DRUG
Intervention: Lidocaine Ointment
Description: Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
Study NCT02805504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
Study NCT02805504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: This group will receive intraoperative Bupivacaine HCl injection at the surgical site.
Study NCT02395302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Action Pneumatic Compression
Description: Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
Study NCT03400956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Orally, coated tablet 2 mg, once daily
Study NCT03400956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orally, coated tablet, once daily
Study NCT02251964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: 2 times 1000mg dose at 14 days interval treatment
Study NCT02251964 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Zr-89-rituximab immuno PET/CT
Description: Immuno labeled PET/CT of the lungs
Study NCT04605367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial stimulation
Description: For both tasks, the training modalities are the same. After the pre-test, this group will physically repeat the correct sequence as many times as possible, during 12 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the real anodal stimulation. The intensity of the current will gradually increase for 30s until it reaches 1mA, will remain constant for 15min, then will gradually decrease for 30s until 0mA is reached. The current density during stimulation will be 0.04 mA/cm². For the manual task the anode will be centered above C4 (according to the international 10-20 EEG system) that is located near the hand area of M1. The cathode will be placed on the supraorbital region ipsilateral to the trained hand (Fp1). For the body task, the anode will be placed in the center of the cortex (Cz) and the cathode will be placed at the medial supraorbital region (Fpz).
Study NCT01589770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cardiac Magnetic Resonance imaging
Study NCT03511898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 dose level 1
Description: single intravitreal injection of THR-149 dose level 1
Study NCT03511898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 dose level 2
Description: single intravitreal injection of THR-149 dose level 2
Study NCT03511898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-149 dose level 3
Description: single intravitreal injection of THR-149 dose level 3
Study NCT01685333 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin Alfa
Description: Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
Study NCT03105466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty
Description: Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
Study NCT03105466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acellular Porcine Cornea
Study NCT03105466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus eye drops
Study NCT03105466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobradex eyedrops
Study NCT04440423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotiazepam 5 mg Test Product Coated Tablets
Description: Investigational Medicinal Product
Study NCT04440423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotiazepam 5 mg Reference Product Coated Tablets
Description: Rize (Trademark)
Study NCT03227809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handbook condition
Description: Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students.
Study NCT03227809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handbook plus condition
Description: Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students. Parent also receive text messages throughout the year.
Study NCT01642628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Education
Description: Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
Study NCT02819908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imprimis Dropless
Description: Tri-Moxi-Vanc transzonular intravitreal injection
Study NCT04581720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF)
Description: Give 4 electrical stimulants on the ulnar nerve to see if the 4 responses (T1 \~ T4) of adductor pollicis fade or not. If there's no neuromuscular block, it shows no fade, or it fades. When an operation is over under general anesthesia, we use the ratio of the height of T4 to T1, and the ratio is over 90%, the neuromuscular block is recovered enough to extubation.
Study NCT02819908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imprimis Less Drops
Description: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
Study NCT03493932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Study NCT01276184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Message
Description: Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit (or as many days as possible depending on when the rescheduled visit will take place - for example, if they call in and reschedule the visit to take place in 4 days, they will receive text messages for the 3 days prior to the rescheduled visit). Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their re-scheduled appointment(s).
Study NCT03241446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilmanocept
Description: Intravenously administered Technetium Tc 99m tilmanocept
Study NCT03493932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
Study NCT03619967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral imager
Description: Device: Bio-inspired multispectral imager~-Manufactured at University of Illinois at Urbana Champaign
Study NCT00243646 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation
Description: All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
Study NCT01349140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
Study NCT00474240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20 mg
Study NCT00474240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEGR-733 5 mg
Study NCT00474240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEGR-733 10 mg
Study NCT00474240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00474240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEGR-733 5 mg + atorvastatin 20 mg
Study NCT00474240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEGR-733 10 mg + atorvastatin 20 mg
Study NCT02673333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT03216460 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Insulet automated glucose control system
Description: Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
Study NCT00243646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron
Description: 9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
Study NCT00887458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
Study NCT00887458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 300mg
Description: Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
Study NCT03437421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: * Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~* Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~* Patients with : 25-OH-D3 \<10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™).
Study NCT02392260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vasculight
Description: Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
Study NCT02504255 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological samplings
Description: Blood, urine and faecal sampling every 3 months
Study NCT02504255 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: patients fill several questionnaires every month to assess stress and adaptation parameters
Study NCT01486420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injections
Description: Corticosteroid injections in and around A1-pulley.
Study NCT01486420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Open A1-pulley release
Study NCT02318784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT03431233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-enriched bar, commercial cereal bar, or water
Description: Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.
Study NCT00243646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Casodex
Description: 9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
Study NCT00043550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Expressive Therapy
Description: The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.
Study NCT00043550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Participants will receive sertraline.
Study NCT00043550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pill Placebo
Description: Participants will receive a pill placebo.
Study NCT00043550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Participants will receive venlafaxine.
Study NCT03259620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS006
Description: Furosemide Topical Gel
Study NCT03259620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS006 Vehicle
Description: Vehicle Topical Gel
Study NCT03635411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside and Pterostilbene
Description: Nicotinamide riboside and pterostilbene manufactured by Basis
Study NCT03635411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Basis supplement.
Study NCT01151943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane (TAP) Block
Description: Bilateral injection of levobupivacaine (20 mL, 3.75 mg/mL)
Study NCT01151943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incisional Infiltration of Local Anesthetic
Description: continuous administration of levobupivacaine (1,25 mg/mL,5 mL/h) during 48 hours.
Study NCT02907190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean Type
Description: 1/2 cup of freshly boiled beans will be eaten by participants on separate study visits
Study NCT02907190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Starchy Foods
Description: 1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
Study NCT04926402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care Education Program
Description: It is a special method of caring for a premature infant in which the baby is positioned for at least 1 hour a day in an upright skin-to-skin and chest-to-chest contact with its mother.
Study NCT03579602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tozuleristide
Description: Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.
Study NCT03579602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Canvas System
Description: All subjects enrolled in the study will have their tissue imaged with the Canvas System.
Study NCT03579602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canvas System
Description: All subjects enrolled in the study will have their tissue imaged with the Canvas System.
Study NCT00492063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell culture-derived trivalent subunit influenza vaccine (cTIV)
Description: One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
Study NCT00492063 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg-derived trivalent subunit influenza vaccine (TIV)
Description: One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle